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Most current articleDiseases of the stomach, including gastric cancer and peptic ulcer, are the most common
digestive diseases. It is impossible to visualize the entire stomach with the passive capsule
currently used in practice because of the large size of the gastric cavity. A magnetically
controlled capsule endoscopy (MCE) system has been designed to explore the stomach. We
performed a prospective study to compare the accuracy of detection of gastric focal lesions by
MCE vs conventional gastroscopy (the standard method).METHODS: We performed a multicenter blinded study comparing MCE with conventional gastroscopy in
350 patients (mean age, 46.6 y), with upper abdominal complaints scheduled to undergo
gastroscopy at a tertiary center in China from August 2014 through December 2014. All patients
underwent MCE, followed by conventional gastroscopy 2 hours later, without sedation. We
calculated the sensitivity, speciﬁcity, positive predictive value, and negative predictive value of
detection of gastric focal lesions by MCE, using gastroscopy as the standard.RESULTS: MCE detected gastric focal lesions in the whole stomach with 90.4% sensitivity (95% conﬁdence
interval [CI], 84.7%–96.1%),94.7%speciﬁcity (95%CI, 91.9%–97.5%), apositivepredictivevalueof
87.9% (95% CI, 81.7%–94.0%), a negative predictive value of 95.9% (95% CI, 93.4%–98.4%), and
93.4%accuracy (95%CI, 90.83%–96.02%).MCEdetected focal lesions in theupper stomach(cardia,
fundus, and body) with 90.2% sensitivity (95% CI, 82.0%–98.4%) and 96.7% speciﬁcity (95% CI,
94.4%–98.9%).MCEdetected focal lesions in the lowerstomach (angulus, antrum,andpylorus)with
90.6% sensitivity (95% CI, 82.7%–98.4%) and 97.9% speciﬁcity (95% CI, 96.1%–99.7%). MCE
detected 1 advanced gastric carcinoma, 2 malignant lymphomas, and 1 early stage gastric tumor.
MCE did not miss any lesions of signiﬁcance (including tumors or large ulcers). Among the 350
patients, 5 reported 9 adverse events (1.4%) and 335 preferred MCE over gastroscopy (95.7%).CONCLUSIONS: MCE detects focal lesions in the upper and lower stomach with comparable accuracy with con-
ventional gastroscopy.MCE is preferredby almost all patients, comparedwith gastroscopy, and can
be used to screen gastric diseases without sedation. Clinicaltrials.gov number: NCT02219529.Keywords: Magnetically Controlled Capsule Endoscopy; Gastroscopy; Gastric Diseases; Diagnostic Accuracy; Screening.rship.
r: CE, capsule endoscopy; CI, conﬁdence
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September 2016 MCE vs Gastroscopy 1267Diseases of the stomach, including gastric cancerand peptic ulcer, are the most common digestive
diseases. Gastric cancer is the fourth most common
cancer globally, and is the second most common cause of
death from cancer worldwide.1 Almost 4% to 17% of the
world population has or has had a peptic ulcer of the
stomach or duodenum.2 Conventional gastroscopy
allows for the accurate localization of lesions, and is the
most effective diagnostic modality for gastric diseases.
Unfortunately, it is invasive and uncomfortable under
nonsedated situations, leading to low patient compliance.
Although sedation can improve patient compliance, its
cost has been a major concern, as well as discomfort and
anesthesia-related adverse events that are encountered
in a few patients after the procedure.3
Capsule endoscopy (CE) was ﬁrst introduced in 2000,
and represents a more patient-friendly alternative
method of examination without signiﬁcant discomfort,
which has been widely applied in clinical practice.4,5
However, complete gastric visualization with the passive
capsule currently used in clinical practice is impossible
because of the large size of the gastric cavity. Recently,
studies have shown that the use of capsules maneuvered
with an external magnetic ﬁeld, so-called magnetically
controlled capsule endoscopy (MCE), may represent a
more reliable approach for gastric examination; several
trials have reported promising results.6–9 However, most
of these studies were pilot studies with a small sample
size, and no large multicenter study has been reported.
A novel MCE system was developed and approved by
the China State Food and Drug Administration in 2013,
which uses a permanent magnetic ﬁeld generated by an
external industrial robot to allow for noninvasive
exploration of the stomach. Two pilot studies have
shown that the MCE system was safe and feasible in
healthy volunteers and a small number of patients.10,11
However, the diagnostic accuracy of MCE for gastric
diseases needs to be conﬁrmed in a large-scale trial.
Therefore, this large prospective multicenter study was
performed to compare the performance of MCE with
conventional gastroscopy in detecting gastric lesions.
Materials and Methods
Study Design
This study was a prospective, self-controlled, multi-
center, blinded comparison study. The study protocol
was approved by the institutional review board of each
participating center. Written informed consent was
obtained from all patients.
Study Patients
Thismulticenter comparative studywas conducted at 7
tertiary referral centers between August 2014 and
December 2014. Adult patients with upper abdominalcomplaints aged 18 to 75 years, who were scheduled to
undergo a gastroscopy,were eligible for this study. Patients
with any of the following conditions were excluded: (1)
dysphagia or symptoms of gastric outlet obstruction, sus-
pected or known intestinal stenosis, overt gastrointestinal
bleeding, history of upper gastrointestinal surgery or
abdominal surgery altering gastrointestinal anatomy, or
postabdominal radiation; (2) congestive heart failure, renal
insufﬁciency, under therapeutic anticoagulation, in poor
general condition (American Society of Anesthesiologists
class III/IV), claustrophobia, metallic parts, a pacemaker or
other implanted electromedical devices, or artiﬁcial heart
valves; (3) pregnancy or suspected pregnancy; (4) exclu-
sion criteria for standard magnetic resonance imaging ex-
amination such as the presence of surgical metallic devices,
even though its low magnetic ﬁeld technically would not
interferewith suchdevices; or (5) currently participating in
another clinical study.Study Intervention
MCE was performed, followed by conventional gastros-
copy 2 hours later, without sedation in eligible patients.
The performance in detecting gastric focal lesions between
MCE and conventional gastroscopy was compared.
Magnetically controlled capsule endoscopy system. The
MCE system was provided by Ankon Technologies Co, Ltd
(Wuhan, Shanghai, China). This system consists of an
endoscopic capsule, a guidance magnet robot, a data
recorder, and a computer workstation with software for
real-time viewing and controlling. The capsule has a size
of 28  12 mm, and contains a permanent magnet inside
its dome. Images are captured and recorded at 2 frames/s
(Supplementary Figure 1A). The view angle of the MCE is
140, and the view distance is 0 to 60 mm. A CMOS image
sensor is used in the MCE. The LED light exposure time
and signal gain of CMOS sensor are adjusted automatically
by measuring the histogram of the image to optimize
brightness and contrast the images. The robot used to
guide the magnet was a C-arm type with 5 df, 2 rotational
degrees and 3 translational degrees. The capsule can be
controlled either manually by a guidance magnet robot
through a joystick or automatically by default mode. The
size of lesions could be measured by the ESNavi software
(Ankon Technologies Co, Ltd, Wuhan, China). Recording
and downloading data are similar to other CEs
(Supplementary Figure 1B).
Gastric preparation regimen and magnetically controlled
capsule endoscopy examination protocol. Patients arrived
at the hospital in the morning after overnight fasting
(>8 hours). In clinical practice, we used simethicone
(Menarini Group, Florence, Italy) as a defoaming agent to
improve gastric mucosal visualization, and pronase
granules (Beijing Tide Pharmaceutical Co, Ltd, Beijing,
China) to remove gastric mucus.12–15 During the
MCE examination, patients were asked to drink 500 to
1000 mL of water on demand.
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was lifted away from the posterior wall, rotated, and
advanced to the fundus and cardiac regions, and then to
the gastric body, angulus, antrum, and pylorus. If
distension was insufﬁcient, water ingestion was
repeated. The MCE gastric examination time was limited
to 30 minutes. All patients were followed up for up to 2
weeks to conﬁrm capsule excretion and any adverse
events. The patients were asked to document the
excretion time of the capsule if they found the capsule in
the stool. If the patients did not found the capsule in 2
weeks, they should come back to the center for conﬁr-
mation by magnetic scanning or abdominal plain radio-
graph examination.
Gastric mucosal cleanliness and visualization. Gastric
mucosal cleanliness and visualization in primary
anatomic landmarks of the stomach including the cardia,
fundus, body, angulus, antrum, and pylorus of the
stomach were evaluated and scored, respectively. A 4-
point grading scale was used to objectively describe
the cleanliness of the stomach during MCE as excellent,
good, fair, or poor (Supplementary Figure 2).16,17
A 3-point grading scale was used to objectively
describe the complete visualization of the gastric mucosa
in the 6 anatomic landmarks in the stomach. The 3-point
grading scale described the visualization of the gastric
mucosa as good (>90% of the mucosa was observed),
fair (70%–90% of the mucosa was observed), and poor
(<70% of the mucosa was observed).
Gastroscopy. Conventional gastroscopy without
sedation was performed by a second experienced
physician who was blinded to the capsule results 2 hours
after capsule ingestion on the same day, and this was
introduced as the standard diagnostic method with
which MCE was compared. Gastric focal lesions were
diagnosed, and their size was measured by either visual
estimation or estimation with the use of open biopsy
forceps during gastroscopy. Gastric biopsy specimens
were obtained if the endoscopist performing the exami-
nation considered the procedure to be clinically neces-
sary. If a focal lesion was obtained by MCE, but not by the
subsequent gastroscopy, a second gastroscopy was per-
formed 1 week after MCE by a senior endoscopist, who
was informed of the false-positive ﬁnding by MCE. We
only used the ﬁrst gastroscopy result for the ﬁnal data
analysis, the second gastroscopy was performed only for
ensuring whether or not there was a focal gastric lesion.
After MCE and gastroscopy, all the patients were asked
if they preferred MCE or gastroscopy. The physician who
performed the MCE and read the real-time gastric capsule
videos and the other physician who performed the
gastroscopy were unaware of each other’s ﬁndings until
completion of the examinations and reports.
Study Outcomes
The primary outcome in the present study was gastric
focal lesion, which was deﬁned as any of the positiveﬁndings including polyp, ulcers, submucosal tumor
(SMT), and others (ie, xanthoma, diverticulum, and so
forth). Erosion, gastritis, and gastric atrophy were deﬁned
as negative ﬁndings because they are diffuse lesions that
can be diagnosed easily by MCE. Secondary outcomes
included gastric cleanliness and mucosal visualization
during MCE, patient compliance, and safety of MCE.
Evacuation of gastric focal lesions, patient compliance,
and safety of MCE. Selected reading speed initially was
set and ﬁxed at 4 frames per second. Evaluation of MCE
was performed by a well-trained physician with experi-
ence of at least 400 capsule endoscopies. CE videos of the
gastrointestinal tract, together with videos of the small
bowel if available, were read and analyzed carefully in
real time and after the procedure. All the ﬁndings in the
esophagus, small bowel, and colon by MCE also were
recorded and disclosed to patients, but we did not report
those data in this article because of the speciﬁcity of the
research design.
Patient compliance for MCE, deﬁned as the tolerance
to procedures of the MCE examination including swal-
lowing of the capsule, drinking plenty of water, and lying
down for at least half an hour, was monitored. Adverse
events, deﬁned as symptoms or signs such as abdominal
distension, nausea, or vomiting, were monitored closely
and recorded by interviewing the patient as an outpa-
tient or by telephone 1, 3, 5, and 7 days, and 2 weeks
after the MCE procedure. Capsule retention (ie, a capsule
endoscope remaining in the digestive tract for a mini-
mum of 2 weeks or a capsule endoscope that requires
directed intervention or therapy to aid its passage) also
carefully was monitored and managed for up to 2 weeks.
Statistical Analysis
For sample size calculation, considering conventional
gastroscopy as the gold standard, our study assumed
that gastric CE has at least 87% sensitivity and 52%
speciﬁcity in detecting patients with gastric focal lesions,
which were separately the lower limit values of the 95%
conﬁdence interval (CI) of 96.00% sensitivity and
77.78% speciﬁcity according to our previous study re-
sults.11 To maintain that hypothesis, as well as the sig-
niﬁcance level of 5% (2-sided) and tolerance error of 6%,
the required positive ﬁndings were estimated to be 60. In
addition, the prevalence of gastric focal lesions was
assumed to be 20% in a population that underwent
routine gastroscopy (according to an unpublished anal-
ysis of gastroscopy results at Changhai Hospital in 2013).
We chose 300 as the study sample size. With an esti-
mated drop-out rate of 15%, a total study size of 345
patients was required.
Per-patient comparisons between conventional
gastroscopy and MCE were performed according to the
type, location, and size of the lesions. If more than 1 focal
lesion was detected in a patient, the most important
clinical-related ﬁnding with the priority of ulcer, SMT,
polyp, and others was chosen as the ﬁnal diagnosis.
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expressed as the mean  SD or median and range values,
where appropriate. Variables pertaining to accuracy
were calculated with a 95% CI (normal approximate)
based on a binomial distribution, in which conventional
gastroscopy was considered to be the standard proce-
dure for detecting focal lesions, and gastroscopy
combined with biopsy was considered the gold standard
procedure for detecting ulcers and cancer. Sensitivity
was calculated as the percentage of patients who had
positive ﬁndings on MCE (of a speciﬁed category) among
those patients who had positive ﬁndings on gastroscopy
(of the same category). Speciﬁcity was calculated as the
percentage of patients who had negative ﬁndings on MCE
(of a speciﬁed category) among patients with negative
ﬁndings on gastroscopy (of the same category), and this
corresponded to 1-the false-positive rate. Statistical an-
alyses were performed with SAS software version
9.3 (SAS Institute, Inc, Cary, NC).
All authors had access to the study data and reviewed
and approved the ﬁnal manuscript.
Results
Patients
A total of 353 patients were enrolled in the
7 participating centers. Three patients (0.8%) refused
further conventional gastroscopy after MCE and were
not included in the analysis. Therefore, 350 patients who
completed the MCE and conventional gastroscopy were
included in the analysis. Among these patients, 186
(53.1%) were male and 164 (46.9%) were female; and
the mean age was 46.6  13.3 years (range, 18–75 y).
A total of 110 patients (31.4%) who were diagnosedTable 1. Prevalence of Gastric Focal Lesions Detected by Con
Gastrointestinal Complaints, and the Performance of M
Lesions
Gastroscopy
Patients, n (%) Patients, n (%)
Typea
Overall 104 (29.7) 107 (30.6)
Polyp 43 (12.3) 47 (13.4)
Ulcerb 30 (8.6) 28 (8.0)
Submucosal tumor 18 (5.1) 17 (4.9)
Othersc 13 (3.7) 15 (4.3)
Locationd
Upper stomach 51 (14.5) 54 (15.4)
Lower stomach 53 (15.1) 53 (15.1)
Size
<5 mm 64 (18.3) 71 (20.3)
5 mm 40 (11.4) 36 (10.3)
aIf a patient has more than 1 focal lesion, the most important clinical-related ﬁndin
the ﬁnal diagnosis.
bIncluding 3 malignant ulcer cases.
cIncluding early gastric cancer, xanthoma, diverticulum, venous aneurysm, telang
dUpper stomach includes the cardia, fundus, and body, and lower stomach incluwith focal lesions or/and atrophic gastritis required
biopsy under gastroscopy. The mean time of the MCE
studies was 26.4  5.1 minutes (range, 20–33 min).Primary Outcome
Prevalence of gastric focal lesions by gastroscopy and
magnetically controlled capsule endoscopy. Table 1 shows
the per-patient prevalence of gastric focal lesions
detected by conventional gastroscopy and the perfor-
mance of MCE for detecting lesions (Figures 1 and 2).
For gastroscopy, 121 focal lesions including polyp
(n ¼ 53), ulcer (n ¼ 34), SMT (n ¼ 19), and others
(n ¼ 15) were found in 104 patients, which represents
29.7% of the patients studied; 85 patients had only 1
kind of focal lesion and 19 patients had at least 2 kinds of
focal lesions in the stomach. Various types of gastritis
were present in the remaining 246 patients.
Among the 104 patients, 24 (23.1%), 27 (26.0%), and
53 (51.0%) patients had focal lesions (the most clinically
related lesion chosen as the ﬁnal diagnosis) located at
the cardia/fundus, body, and angulus/antrum, respec-
tively. Sixty-four (61.5%) patients had lesions less than
5 mm in size, and 40 (38.5%) patients had lesions more
than 5 mm in size. MCE detected 128 focal lesions
including polyp (n ¼ 57), ulcer (n ¼ 32), SMT (n ¼ 17),
and others (n ¼ 22) in 107 patients. Gastritis was pre-
sent in the remaining 243 patients. Gastric focal lesions
were observed in 10 patients by gastroscopy, whereas
gastric focal lesions were observed in 13 patients by
MCE (Tables 1 and 2).
Performance of magnetically controlled capsule endos-
copy in detecting gastric focal lesions. With conventional
gastroscopy as the gold standard, the sensitivity, speci-
ﬁcity, positive predictive value, and negative predictiveventional Gastroscopy and MCE in 350 Patients With Upper
CE Compared With Gastroscopy
MCE
Sensitivity, % (95% CI) Speciﬁcity, % (95% CI)
90.4 (84.7–96.1) 94.7 (91.9–97.5)
90.7 (82.0–99.4) 96.7 (94.4–98.9)
90.0 (73.5–97.9) 99.6 (97.6–99.9)
88.9 (65.3–98.6) 99.6 (97.6–99.9)
92.3 (64.0–99.8) 98.7 (96.3–99.7)
90.2 (82.0–98.4) 96.7 (94.4–98.9)
90.6 (82.7–98.4) 97.9 (96.1–99.7)
92.2 (85.6–98.8) 95.1 (92.4–97.8)
87.5 (77.3–97.8) 99.6 (97.6–99.9)
g with the priority of ulcer, submucosal tumor, polyp, and others was chosen as
iectasia, and ectopic pancreas.
des the angulus, antrum, and pylorus.
Figure 1. Representative
polyps observed on con-
ventional gastroscopy and
MCE. (A–C) MCE exami-
nation and (D–F)
gastroscopy.
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90.4% (95% CI, 84.7–96.1), 94.7% (95% CI, 91.9–97.5),
87.9% (95% CI, 81.7–94.0), and 95.9% (95% CI,
93.4–98.4), respectively. Diagnostic accuracy was 93.4%
(95% CI, 90.83–96.02) (Table 1).
The sensitivity and speciﬁcity of MCE in detecting
focal lesions in the upper stomach (including the cardia,
fundus, and body) were 90.2% (95% CI, 82.0–98.4) and
96.7% (95% CI, 94.4–98.9), respectively; whereas the
sensitivity and speciﬁcity of MCE in detecting focal le-
sions in the lower stomach (including the angulus,
antrum, and pylorus) were 90.6% (95% CI, 82.7–98.4)
and 97.9% (95% CI, 96.1–99.7), respectively. The
sensitivity and speciﬁcity of MCE in detecting focal le-
sions less than 5 mm were 92.2% (95% CI, 85.6–98.8)Figure 2. Representative
ulcers observed on con-
ventional gastroscopy and
MCE. (A and B) Benign
ulcers observed by MCE,
(C) malignant ulcers
observed by MCE, and
(D–F) the corresponding
ulcer images observed by
gastroscopy.and 95.1% (95% CI, 92.4–97.8), respectively; and the
sensitivity and speciﬁcity of MCE in detecting focal le-
sions that are 5 mm or larger were 87.5% (95% CI,
77.3–97.8) and 99.6% (95% CI, 97.6–99.9), respectively
(Table 1).
Large gastric ulcers (>10 mm) were detected by
conventional gastroscopy in 3 cases; wherein 2 were
diagnosed with malignant lymphoma and 1 was diag-
nosed with gastric cancer by pathologic examination.
Ulcers also were detected by MCE in all 3 cases. An early
gastric cancer in the gastric antrum was detected by both
MCE and gastroscopy in a 68-year-old man, and the 0.5 
0.6 cm lesion was removed successfully by endoscopic
submucosal dissection. Pathologic results suggest that it
was high-grade intraepithelial neoplasia and focal
Table 2. The Four-Fold Table Showing the Results of Gastric
Focal Lesions andGastritis Detected by Conventional
Gastroscopy and MCE in the 350 Patients
Gastroscopy
Total,
n (%)
Focal lesions,
n (%)
Gastritis,
n (%)
MCE Focal lesions 94 (26.9%) 13 (3.7%) 107 (30.6%)
Gastritis 10 (2.8%) 233 (66.6%) 243 (69.4%)
Total 104 (29.7%) 246 (70.3%) 350 (100%)
September 2016 MCE vs Gastroscopy 1271adenocarcinoma in the gastric mucosa. The patient
recovered well (Figure 3).
Among the 10 false-negative cases, MCE missed SMTs
in the fundus in 2 cases, ulcers in 3 cases (9.7%, one each
in the antrum, body, and angulus), polyps in 4 cases (2 in
the antrum, 1 each in the body and fundus), and mucosal
uplift in 1 case (in gastric fundus, inﬂammation
conﬁrmed by pathologic examination). In addition, 5
(50%) of these missed lesions were less than 5 mm in
size, and 4 (40%) were located in gastric fundus.
Among the 13 false-positive cases, MCE detected 13
lesions: 8 polyps, 1 SMT, 1 ulcer (3.2%), 2 xanthomas,
and 1 diverticulum. Among these 13 lesions, 11 (84.6%)
lesions were conﬁrmed by a second gastroscopy
including 7 polyps, 1 SMT, 1 ulcer, 1 xanthoma, and 1
diverticulum (Figure 4).
Safety Outcomes
Patient compliance and adverse events of magnetically
controlled capsule endoscopy. All patients were able to
swallow the capsule. No capsule retention occurredduring
the 2-week follow-up period, which was conﬁrmed by
magnetic scanning or abdominal plain radiograph exami-
nation. All patients excreted the capsule spontaneously,
except for 1 patient who had duodenal ulcer complicatedFigure 3. Early gastric
cancer was observed on
MCE and conventional
gastroscopy. (A) MCE, (B)
narrow-band imaging by
MCE, (C) gastroscopy, (D)
narrow-band imaging by
gastroscopy, (E) endo-
scopic submucosal
dissection, and (F)
pathology.with stenosis. The retained capsule was extracted endo-
scopically on the same day by gastroscopy.
A total of 9 adverse events were reported in 5 (1.4%)
of the 350 patients who completed this study. Three
patients had abdominal distension and nausea, 1 patient
had headache and vomiting, and 1 patient had foreign
body sensations. In 4 of these 5 patients, adverse events
including abdominal distension, nausea, vomiting, and
headache were considered to be related to gastric
preparation. All reported symptoms were resolved
within 24 hours after ingestion of the capsule. Among the
350 patients, 335 (95.7%) preferred MCE, 4 (1.1%)
preferred conventional gastroscopy, and 11 (3.1%) had
no preference.
Secondary Outcomes
Gastric cleanliness and mucosal visualization during
magnetically controlled capsule endoscopy. Gastric clean-
liness was considered to be excellent or good in the cardia,
fundus, body, angulus, antrum, and pylorus of the stomach
in 80.9%, 87.2%, 90.9%, 96.0%, 96.6%, and 97.7% of
patients undergoing MCE, respectively. Gastric mucosa
visualization was considered to be good in 75.2%, 73.2%,
88.7%, 92.3%, 96.6%, and 97.4% of patients, respectively,
in the 6 primary anatomic landmarks.
Discussion
This large, prospective, multicenter, blinded study
showed that MCE is a safe method of visualizing the
gastric mucosa through remote magnetic manipulation
without the need for intubation or sedation. Sensitivity
and speciﬁcity of MCE for detecting gastric focal lesions
were acceptable in comparison with gastroscopy. More-
over, because of the noninvasiveness, more than 95% of
patients preferred MCE as an initial diagnostic method.
MCE would be a promising alternative examination
for gastric diseases.7,18–21 First, MCE could be a reliable
Figure 4. Representative
images illustrating gastric
focal lesions missed by
MCE or gastroscopy. Up-
per panel: lesions missed
by MCE. (A) Polyp, (B)
small ulcer, and (C) sub-
mucosal tumor. Lower
panel: lesions missed by
the ﬁrst gastroscopy. (D
and E) Polyps and (F)
gastric diverticulum.
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lesions not requiring further invasive methods, such as
gastroscopy. In this study, there were 110 patients
(31.4%) who required biopsy by gastroscopy. Therefore,
nearly 70% of patients did not need an invasive
gastroscopy after MCE examination. Second, MCE would
be a promising alternative for high-risk patients with
peptic ulcers or gastric cancer, ensuring that early le-
sions would be detected. Interestingly, an early gastric
cancer was detected by MCE in this study. The most
important lesion for esophagogastroduodenoscopy, at
least in Asia, appears to be early gastric cancer. Images of
early gastric cancer shown by Asian investigators often
show a very subtle ﬂat lesion. MCE seems to be more
sensitive than conventional gastroscopy. However, the
possibility of whether MCE could represent an effective
tool for early gastric cancer screening needs to be vali-
dated by further studies. Third, even in regions with a
lower expected prevalence rate of gastric pathologies,
some patients who may have a contraindication for
sedation are afraid of or reluctant to undergo gastros-
copy, MCE could be a very patient-friendly examination.
A prevalence rate of approximately 30% for gastric
focal lesions is more realistic for an average-risk
population in a routine gastroscopy setting. In the pre-
sent study, all types of gastritis were deﬁned as a
negative ﬁnding because almost all types of gastritis are
diffuse lesions, and diagnosing these diseases was not a
challenge for MCE. Although conventional gastroscopy is
the gold standard for diagnosing gastric lesions, 13 focal
lesions were detected by MCE, which was missed by
gastroscopy. Taking into account the painlessness and
high acceptance rate, MCE is a good ﬁlter test routine
that has high sensitivity and speciﬁcity in clinical prac-
tice for gastric examinations such as gastric cancer
screening.Adverse events reported by the patients were rare
and mild, and most of these were attributed to the
preparation, in which patients ingested plenty of water.
In the present study, only patients with upper abdominal
complaints were included, and the retention rate of the
capsule in those patients is believed to be lower than in
patients who were suspected of small-bowel diseases.
Taken together, our results support that MCE, indicated
for detecting gastric diseases, is safe and has a very low
complication rate.22
Although MCE in this study has proven to be com-
parable in diagnostic accuracy with conventional
gastroscopy, there were still some limitations or disad-
vantages. First, the preparation for MCE is more
complicated than that for conventional gastroscopy.
Second, it takes 30 minutes to ﬁnish the MCE process,
which is slightly longer than conventional gastroscopy,
and this requires more strict training and experience for
endoscopists. Third, the current cost of MCE is a little
higher than conventional gastroscopy but the cost will
decrease if it is used widely in the future. Fourth, the
higher acceptability of MCE observed in this study might
be biased by the fact that gastroscopy was performed
without sedation.
In summary, this novel MCE has high diagnostic ac-
curacy compared with conventional gastroscopy, and is a
promising alternative for patient-friendly screening for
gastric diseases.Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at http://dx.doi.org/10.1016/j.cgh.2016.05.013.
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Supplementary Figure 1. The NaviCam capsule endoscope and magnetic control system. (A) The NaviCam capsule endo-
scope (Ankon Technologies Co, Ltd, Wuhan, China). The capsule has a size of 28  12 mm, and contains a permanent magnet
inside its dome. The view angle of the MCE is 140, and the view distance is 0–60 mm. A CMOS image sensor is used in the
MCE. The LED light exposure time and signal gain of the CMOS sensor are adjusted automatically by measuring the histogram
of the image to optimize brightness and contrast of the images. (B) The NaviCam magnetic control system. The magnetic ﬁeld
generated by the MCE can be adjusted, and can reach a maximum of 200 mT. The capsule location was obtained through a
simulation, based on the magnetic ﬁeld generated by the guidance system. There are gravity and magnetic sensors inside the
capsule. The gravity sensor can be used to measure the angle between the orientation of the capsule and the direction of
gravity, the magnetic sensor can measure the external magnetic ﬁeld. The external magnet with its magnetization direction
along the direction of gravity moves around by the robot, and the MCE sensor values are read and transmitted to the com-
puter. By a programmed search process, the external magnet can be located just above the capsule. At this synchronization
position, while the external magnet rotates, the capsule also rotates, and the capsule’s orientation and location can be
calculated. The external magnet moves according to the calculation results so that it always stays just above the small magnet
of the capsule. In case the external magnet and the capsule are out of location synchronization, the search process can be
used to ﬁnd the capsule again. Although the robot can be controlled manually, this automatic process greatly can reduce the
complexity to navigate the capsule inside the stomach.
1273.e1 Liao et al Clinical Gastroenterology and Hepatology Vol. 14, No. 9Supplementary Figure 2. Representative images showing the 4-point grading scale used to objectively describe the clean-
liness of the stomach during magnetic capsule endoscopy. (A) Excellent, no more than small bits of adherent mucus and foam.
(B) Good, small amount of mucus and foam, but not enough to interfere with the examination. (C) Fair, considerable amount of
mucus or foam present to preclude a completely reliable examination. (D) Poor, large amount of mucus or foam residue.
